GNFTF News and Press, Genfit Ord From 03/24/20

Introduction It is remarkable how few articles have been published about Genfit ( GNFT) lately on Seeking Alpha. The last articles dated from June and August last year. This is quite remarkable since the company is nearing its make-or-break moment and indicates that investors’ ...

Esperion Gets FDA Nod for Nexletol Esperion Therapeutics (ESPR) reported that its lead drug candidate Nexletol has been approved by the FDA for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. The treatment has ...

Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...

This past week, Intercept Pharmaceuticals ( ICPT ) was notified by the FDA that its PDUFA date for Ocaliva to treat patients with NASH would be delayed to June 26, 2020. However, any potential weakness or downtrend in the stock in the coming months should be viewed as a great buying opport...

Introduction Much has been made of the NASH race, which came to a pinnacle of hype in 2018 with stocks like Madrigal ( MDGL ) & Viking ( VKTX ) quadrupling in value. The mood has since subdued, as the realization of competition and the hurdles to market have set in. Genfit ( OTCPK:GNF...

Gilead Sciences ( GILD ) announced two key news items recently. It started off with positive proof of concept NASH results with a double combination treatment, which was presented at the International Liver Congress 2019. Then a few days later, it announced a partnership with Novo Nordisk ( NV...

Madrigal Pharmaceuticals ( MDGL ) is a US biotech company that currently has only one drug, MGL-3196, under clinical investigation stage. Being Madrigal’s key asset, MGL-3196 has proven its strong potential in Non-Alcoholic Steatohepatitis ((NASH)) and is currently advancing to Phase ...

The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne...

Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha...

Loos, France-based Genfit S.A. ( OTCPK:GNFTF +2.6% ) has filed a preliminary prospectus for an initial public offering (IPO) of 5M American Depositary Shares (ADSs), applying for the ticker symbol "GNFT." More news on: Genfit SA, Healthcare stocks news, IPO News, Stocks on the move, ...